BTK

Sigaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2680 Ibrutinib (PCI-32765) <1 mg/mL 88 mg/mL <1 mg/mL
S7173 CC-292 (AVL-292) <1 mg/mL 85 mg/mL <1 mg/mL
S7257 CNX-774 <1 mg/mL 100 mg/mL 2 mg/mL
S7080 RN486 <1 mg/mL 62 mg/mL <1 mg/mL
S7734 LFM-A13 <1 mg/mL 72 mg/mL <1 mg/mL
S8166 ONO-4059 (GS-4059) hydrochloride <1 mg/mL 98 mg/mL 1 mg/mL
S8116 ACP-196 <1 mg/mL 93 mg/mL 93 mg/mL
S7877 ONO-4059 analogue <1 mg/mL 20 mg/mL <1 mg/mL
S7051 CGI1746 <1 mg/mL 100 mg/mL 33 mg/mL
Catalog No. Information Product Use Citations Product Validations
S2680

Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

S7173

CC-292 (AVL-292)

CC-292 (AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

S7257

CNX-774

CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.

S7080

RN486

RN486 is a potent and selective BTK inhibitor with IC50 of 4 nM.

S7734

LFM-A13

LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.

S8166New

ONO-4059 (GS-4059) hydrochloride

ONO-4059 (GS-4059) is highly potent and selective BTK inhibitor with an IC50 of 2.2 nM.

S8116New

ACP-196

Acalabrutinib(ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.

S7877

ONO-4059 analogue

ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.

S7051

CGI1746

CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.

Catalog No. Information Product Use Citations Product Validations
S2680

Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

S7173

CC-292 (AVL-292)

CC-292 (AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. Phase 1.

S7257

CNX-774

CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.

S7080

RN486

RN486 is a potent and selective BTK inhibitor with IC50 of 4 nM.

S7734

LFM-A13

LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.

S8166New

ONO-4059 (GS-4059) hydrochloride

ONO-4059 (GS-4059) is highly potent and selective BTK inhibitor with an IC50 of 2.2 nM.

S8116New

ACP-196

Acalabrutinib(ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.

S7877

ONO-4059 analogue

ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.

S7051

CGI1746

CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.